Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424840 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
A Phase 1 study, sponsored by University of Massachusetts, Worcester.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00424840 is a Phase 1 study that was terminated before completion, run by University of Massachusetts, Worcester. The registered enrollment target is 12 participants.
The verdict
NCT00424840, a Phase 1 study, was terminated before completion, sponsored by University of Massachusetts, Worcester.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC). Phase I and II study of this combination in first line setting will be conducted in order to properly estimate the efficacy and safety of this regimen. This will form the basis for future studies comparing this combination to what is now considered standard regimen for first line therapy in patients with NSCLC, carboplatin, paclitaxel and bevacizumab.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin AUC 6
- DRUG Bortezomib 1.3 mg/m2
- DRUG Bortezomib 1.6 mg/m2
- DRUG Bortezomib 1.8 mg/m2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-06 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424840
The ClinicalTrials.gov registry entry for NCT00424840 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00424840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00424840 about?
NCT00424840 is a clinical study titled "Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy". A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC). Phase I and II study of this combination in first line setting will be conducted in order to properly estimate the efficacy and safety of this...
What is the current status of trial NCT00424840?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-06. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00424840?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin AUC 6 (DRUG), Bortezomib 1.3 mg/m2 (DRUG), Bortezomib 1.6 mg/m2 (DRUG), Bortezomib 1.8 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT00424840?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.